Reverse transcriptase is a part of HIV required to infect cells in the body and make mor virus. NNRTIs stop the reverse transcriptase from working properly, like the nucleoside analogue reverse transcriptase inhibitor drugs.
A new third calss of HIV drugs, that act to directly combine with and block the action of HIV's enzyme.
Compounds that inhibit an RNA-directed DNA polymerase, that do not mimic nucleosides.
a new class of drugs used to treat HIV infection.
The third class of anti-HIV drugs, NNRTIs bind near reverse transcriptase's active site and subsequently inhibit its polymerase activity. Approved NNRTIs include delavirdine, efavirenz, and nevirapine.
The newest class of antiretroviral drugs that work by inhibiting the reverse transcriptase enzyme necessary for HIV replication.
A group of structurally diverse compounds that bind to the catalytic site of HIV-1's reverse transcriptase. As noncompetitive inhibitors of reverse transcriptase, their antiretroviral activity is additive or synergistic with most other antiretroviral agents.
A group of structurally different compounds that bind to the catalytic site of HIV-1's reverse transcriptase. They are quite specific; unlike the nucleoside reverse transcriptase inhibitors, the NNRTIs have no activity against HIV-2. Included in this class of drugs are nevirapine, delavirdine, efavirenz, and tenofovir.
A class of antiretroviral drugs, including Efavirenz, Delavirdine Mesylate and Nevirapine, that act to combine directly with and block the action of HIV's reverse transcriptase. In contrast, Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) block reverse transcription by capping the unfinished DNA chain that the reverse transcriptase is constructing. A disadvantage of NNRTIs is the ability of HIV through one single mutation to become resistant to all members of this class.
Group of HIV medications that bind to a specific part of the virus and inhibit its growth. They are very specific in their target and only have a killing effect on HIV-1, not HIV-2. Their antiviral activity is greatly increased when given in combination with other antiretroviral agents.